Clinical Trials
22 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06246643 2026-05-19
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
Phase 2 Active not recruiting
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT07379047 2026-04-24
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
NCT07483684 2026-03-19
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06137170 2026-03-02
RegoSeq
Bayer
Completed
NCT07392866 2026-02-09
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3 Not yet recruiting
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07384377 2026-02-03
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07310173 2025-12-30
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 2 Recruiting
NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT05425940 2025-10-23
STELLAR-303
Exelixis
Phase 3 Active not recruiting
NCT04660812 2025-10-20
ARC-9
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting